Category:

Kelly Davio, Welcome to This Week in Managed Care from the Managed Markets News Network

Pharmaceutical companies hope computers can help them find new medications that are faster, cheaper—and more likely to be effective...The idea is that machines, which are adept at pattern recognition, can sift through vast amounts of new and existing genetic, metabolic and clinical information to unravel the complex biological networks that underpin diseases. That, in turn, can help identify medications likely to work in specific patient populations, while simultaneously steering companies away from drugs that are likely to fail...In the past, drug companies have used artificial intelligence to examine chemistry—whether a drug might bind to a particular protein, for instance. But now the trend is to use AI to probe biological systems to get clues about how a drug might affect a patient’s cells or tissues...Biological insights driven by machine learning also could help pharmaceutical companies better identify and recruit patients for clinical trials of therapies most likely to work for them, perhaps boosting the chances of those medications’ getting approved by regulatory agencies...The big difference between AI-driven drug trials and traditional ones...is "we’re not making any hypotheses up front. We’re not allowing [human] hypotheses to generate data. We’re using the patient-derived data to generate hypotheses."

Kelly Davio, Welcome to This Week in Managed Care from the Managed Markets News Network

Nicole Crisano, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Nicole Crisano, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Mobile health has become increasingly popular as the healthcare world moves towards value and away from volume, according to a new study by GBI Research. mHealth can connect patients with numerous healthcare services, while also collecting valuable data...This approach has already had an impact on the healthcare industry and numerous organizations are making investments in the technology. mHealth can also be used to encourage patients to adhere to their treatments, providing physicians with an additional way to communicate beneficial behaviors to their patients... advances in mobile technology, the expansion of communication, and the reduction in the cost of wireless technology...have huge potential to bridge the gap within existing healthcare systems, offering an alternative form of healthcare communication and treatment at a distance...The most important driver behind mHealth is the growing need for cost-effective ways to provide healthcare...Another important driver is the shift towards value-based care and reimbursement...healthcare providers are interested in helping patients achieve optimal outcomes rather than being incentivized to order more tests or perform more services.

Centers for Disease Control and Prevention...Prescriptions per capita, measured in morphine equivalents to account for various strengths and drug types, have declined steadily since their 2010 peak...Half the nation’s counties saw a decline (a quarter were stable) from 2010 to 2015. But there was wide variation, with providers in the highest-prescribing counties writing scripts for six times more opioids per resident than those in the lowest-prescribing counties...Nationally, the epidemic has been driven by high rates of addiction in more rural and white areas...Looking at county-level prescribing data helped CDC researchers to shed more light on some patterns of the painkiller epidemic. Counties with high rates tended to:

• Contain small cities or large towns (perhaps with pharmacies that drew residents from rural areas)
• Have higher percentages of white residents
• Have more dentists and primary-care physicians per capita
• Have more residents who were uninsured or unemployed
• Have more people with diabetes, arthritis, or a disability

But county-by-county analyses also illustrated how much is unknown about where and why opioids are given.

Computer simulations may get a role alongside human testing as part of an effort to bring new medications and medical devices to market more quickly and cheaply...The...Food and Drug Administration outlined a proposal...to help integrate computer modeling and virtual testing as part of the regulatory approval process for manufacturers -- a step the agency said could save money while helping find cures for puzzling conditions such as Alzheimer’s disease...The average cost of developing a new medication is about $2.56 billion...and much of that goes to fulfilling the FDA’s rigorous demands for proving safety and effectiveness...The price of new technology affects the ability of people to access these new treatments...We therefore need to be mindful of the costs of our regulatory processes, to the degree that these costs also affect the availability of new innovations, and the way that they are ultimately priced…The idea of computer simulated experiments, sometimes called in silico trials, has been around for years but the FDA hasn’t provided guidance to allow the drug industry to use it in testing...The FDA has begun using computer modeling to build databases to help researchers predict how new treatments...will perform. And the agency is developing a family of "virtual patients" for testing new devices…

Nicole Crisano, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Kelly Davio, Welcome to This Week in Managed Care from the Managed Markets News Network